<SEC-DOCUMENT>0001193125-15-011426.txt : 20150115
<SEC-HEADER>0001193125-15-011426.hdr.sgml : 20150115
<ACCEPTANCE-DATETIME>20150115091629
ACCESSION NUMBER:		0001193125-15-011426
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150115
FILED AS OF DATE:		20150115
DATE AS OF CHANGE:		20150115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15528513

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d852948d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of January, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 15 January 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g852948001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Shares on issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">246 M</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of
Directors</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman &amp; Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15 January 2015</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN ANNOUNCES IMPORTANT DISCOVERY IN REGENERATIVE MEDICINE PROGRAM</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX:<I>NRT</I>; NASDAQ:<I>NVGN</I>), an Australian/US biotechnology
company, today announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regenerative medicine is concerned with repairing or replacing tissue lost due to age,
disease, damage or congenital defects. In the case of the brain, damage associated with stroke, head trauma or neurodegenerative disease represents a very significant unmet clinical need for such therapies.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen scientists now in an important scientific breakthrough have identified a family of
compounds with an ability to promote the growth and activity of normal brain stem cells.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dominant approach being taken to brain regeneration is the introduction of tissue stem cells that have been cultured outside of the body. However, delivery
of these cells through the skull is very invasive and, so far, these cells seem to be susceptible to the same constraints that limit the resident stem cell population.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Work in the 1990&#146;s showed that the old adage, &#145;We continue to grow brain cells until age 21, and from then on it&#146;s all downhill&#146;, was, in
fact, untrue. Close examination revealed that part of the hippocampus, the main site of learning and memory within the brain, is constantly renewed throughout life by a pool of dividing stem cells. A second discrete pool of stem cells generates
daughter cells that can migrate to sites of brain damage to facilitate repair. Unfortunately, for reasons that are not currently understood, these migrating stem cells fail to produce enough new neurons in the damage site to provide substantial
recovery.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen adopted the alternative approach of seeking drugs that would promote
the migration of stem cells to the site of injury, seek to retain those stem cells at the damaged site, and then promote their regenerative capacities. This offered the potential of a non-invasive, well-tolerated, medicinal approach to a widespread
problem.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, Novogen established a partnership with Genea Biocells, an
Australian company with world-leading expertise in the production, growth and development of human embryonic stem cells. The original purpose of that collaboration was to mine the Company&#146;s super-benzopyran drug technology platform for new
therapies with the capacity to repair aberrant stem cells in people with various neurodegenerative disorders (eg. motor neurone disease) and musculodegenerative disorders (eg. muscular dystrophies).</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">That program recently was extended to look at the ability of that same drug platform to
stimulate the growth of healthy brain stem cells to create new nerve cells. That has been achieved in what is the first key step in the path to the development of a new family of drugs to treat brain injury.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page&nbsp;&nbsp;|&nbsp;&nbsp;<B>2</B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the central pharmacophore now identified as displaying this activity, a medicinal chemistry program now
is underway to produce a lead candidate compound that will be taken into an animal model that replicates human brain injury. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Brown PhD, Novogen
Group CSO, said, &#147;Some years ago, we saw evidence with one of our early drugs of an ability to promote the function of nerve cells, even to the extent of protecting nerve cells from damage by cytotoxic drugs. But it is only now with the advent
of our super-benzopyran drug platform that we are seeing a more profound effect to the extent of promoting the activity of the all-important brain stem cells. Now we have the basis of a drug development program.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graham Kelly PhD, Novogen Group CEO and Executive Chairman, said, &#148;The development of anti-cancer drugs remains our overriding focus. But what this
discovery announced today does is to demonstrate the enormous potential of our intellectual property across many areas of medicine as the basis for Novogen working to become a global drug discovery company across broad therapeutic fields.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian
drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ (&#145;NVGN&#146;). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full
heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial
disintegration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM compounds target the micro-filament component of the cancer cell&#146;s cytoskeleton and have been designed to combine with
anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company pipeline
comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate (&#145;Anisina&#146;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on
our websites <U>www.novogen.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Graham Kelly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chairman &amp; CEO Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4100</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cristyn Humphreys</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating Officer Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cristyn.Humphreys@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472
4111</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g852948002.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g852948001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g852948001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"4`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]1;G4OL\S1^7NQCG=C^E1?VS_`-,1_P!]_P#UJK:G_P`?C_0?RJK0
M!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_Z8C_`+[_
M`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS_P!,1_WW
M_P#6H_MG_IB/^^__`*U9E%`&G_;/_3$?]]__`%J/[9_Z8C_OO_ZU9E%`&G_;
M/_3$?]]__6H_MG_IB/\`OO\`^M6910!I_P!L_P#3$?\`??\`]:C^V?\`IB/^
M^_\`ZU9E*,9%`%AO$^&(^S=#_P`]?_K4G_"4?].P_P"_O_UJYR_OH+!6>ZD5
M,Y*@GEOH*Y;4_%$UR"ED&@C/4Y^8_P"%5&-S&K7A#=ZG>ZE\0[;3%(EMR\N,
MB-)<G\>.*RA\601D:5_Y-?\`V->>$DDDDDGKFDK3D1PSQ<V_=T/1?^%L_P#4
M*_\`)K_["C_A;/\`U"O_`":_^PKSJBCD1'UFKW_(]%_X6S_U"O\`R:_^PH_X
M6S_U"O\`R:_^PKSJBCD0?6:O?\CT7_A;/_4*_P#)K_["C_A;/_4*_P#)K_["
MO.J*.1!]9J]_R/1?^%L_]0K_`,FO_L*5/BPA=1+IC*A/)6XW$?AMKSFBCD0U
MB:O<]BM?&<-['OMH5=>^)>GZ5-_PE'_3L/\`O[_]:O';:ZFM)`]M(T;CNIZ_
M7UKI--\5(X6/40$;IYB_=/U]*B4+;'72Q49:2T9WW_"4?].P_P"_O_UJ/^$H
M_P"G8?\`?W_ZU8,;K*@>)E9&'!!SFEJ#KZ7-W_A*/^G8?]_?_K4?\)1_T[#_
M`+^__6K"HH`W?^$H_P"G8?\`?W_ZU'_"4?\`3L/^_O\`]:L*B@#=_P"$H_Z=
MA_W]_P#K4?\`"4?].P_[^_\`UJPJ*`-W_A*/^G8?]_?_`*U36_B#SRW^C[=H
M_P">F?Z5SE6]/ZR?04`;O]L_],1_WW_]:C^V?^F(_P"^_P#ZU9E%`&G_`&S_
M`-,1_P!]_P#UJ/[9_P"F(_[[_P#K5F44`:?]L_\`3$?]]_\`UJ/[9_Z8C_OO
M_P"M6910!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_
MZ8C_`+[_`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS
M_P!,1_WW_P#6I#K849:(#_@?_P!:LN1_+7(&:K/(7.6H`V#XB':#/_`__K4?
M\)%_T[_^1/\`ZU8M%`&U_P`)%_T[_P#D3_ZU'_"1?].__D3_`.M6+10!M?\`
M"1?]._\`Y$_^M1_PD7_3O_Y$_P#K5BT>M`#-2^)']G7LMN=.\SR\?-]HQG(!
MZ;?>JW_"UO\`J%G_`,"O_L:Y3Q+_`,ANY_X!_P"@BLL^O:MHQ6AYE3$5%-I,
MZW5OC-=Z<IDM_#OVN(#+%-0PR_5?+_E6`/VE\D`>&R23@#^T>_\`W[J*VL);
MC!`")ZFEN/"]B-]Q#!&MV%XE"@%C5KV2T:.:I+&O6%2R]%_D=#I_QKN;N/?<
M^'OLJD94-J&6/U'EC%6_^%P_]0C_`,G/_L*\X)Z4E-TX=B%C*Z5G+\%_D>D?
M\+B_ZA/_`)-__84?\+B_ZA/_`)-__85YO11[.(_KM?\`F_(](_X7%_U"?_)O
M_P"PH_X7%_U"?_)O_P"PKS>BCV<0^NU_YOR/2/\`A<7_`%"?_)O_`.PH_P"%
MQ?\`4)_\F_\`["O-Z*/9Q#Z[7_F_(](_X7%_U"?_`";_`/L*HZC\;KJR7?!X
M<-S&!\VV_P`,/P\O^M<+2AJ:IP6Z%+%UVM)V^2_R-\?M,#OX<(_[B/\`]KH_
MX:87_H7?_*C_`/:JXS5/#]KJ8+%1%,>DBCK]1WKD=3\/76F$ET\R(?\`+1.G
MX^E;0I4I=#SJN.S"GKSW7HO\CV'_`(:87_H7?_*C_P#:J/\`AIA?^A=_\J/_
M`-JKPS'%&*OZM2['/_;&-_G_``7^1[G_`,-,+_T+O_E1_P#M5+_PTPO_`$+O
M_E1_^UUX7BN^\%_#@:M;0ZAK#LMK+\R01\,Z^I/8?3FIG1HQ5VC?#X_,:\^6
MG*[]%_D>A:3\?[W6[GR-,\*23-_$?[1PJCU)\K`%=U;^-9'A4W-@D<I'S(ES
MO`_':/Y5RUCI]MIELL&GP1P0KT5%Q^?K4]<<^1_"K'TV'A7BOWL[OT2.JB\6
M>:#_`*+C'_37_P"M4R^)03AK<J/7S,_TKF;3HWX5;K)[G4MCHAK8896($?[_
M`/\`6I?[9_Z8C_OO_P"M7.JQ1LJ<&K4-QYAVL,-_.D,V/[9_Z8C_`+[_`/K4
M?VS_`-,1_P!]_P#UJS**`-:#53/,J>5MW'&=^?Z5H5@V/_'W%_O5O4`8>I_\
M?C_0?RJK5K4_^/Q_H/Y55H`****`"BBB@`HHHH`****`"BBB@`I0,TG0<]JQ
M]3\3P6>4M?W\HZ[?NC\>]-)LF4HQ6KL:TLL<$9>9U1!U9C@5SNJ>*PKE-+&[
MG'FL/Y#_`!K"O-0N-1?==R,P!X4<*/H*@QCI6B@CSZV+E+2.B,RYN9+N9I+E
MVD<D\L<U%2GJ?K25?2QR!1110`4444`%%%%`!1110`4444`%%%%`BY8ZK<Z>
M3]GE(4]48Y!_"NIT[Q';7VU)3Y,Q_A)^4_0UQ5`XS[U+BF;TJ\H:'I=%<3IO
MB*YL"$D8SQ=-C'D#V/\`C75:?JUMJ2`V[X?',;<,*AP:/1IUX36^I<HHHJ#8
M****`"K>G]9/H*J5;T_K)]!0!:HHHH`****`"BBB@`HHHH`****`"BBB@!ES
M_JQ56K5S_JQ56@`HHHH`****`"@#)XHIK-@\4`<=K]N]QK=P(@3]S)QP/E%)
M;Z:D6#+\[>O85JZC_P`?LA/?'\A5:MNAYSI+F;`<#`IDOW&_W33Z9+]QO]TT
M%2V..-)2M25NMCQY;A1110(****`"BBB@`HHHH`*&PP(8`@]11136@&%JGA.
MWO`9+'_1YO3/R-^':N2O=.N-/EV7<;(W8GH?H:]*ID]O%=1&.XC1T/4,,U<*
MC3U.6KA(SU6C/+Z]]\%?\BII7_7LM>5ZIX-*AI-,?/<Q.?Y'_&O5O!T;1>&-
M-212K);JK`CH:6(:<4S?):,Z>(ES=OU-FBBBN0^H+5IT;\*MU4M.C?A5NLWN
M4M@J6V_UP^A_E452VW^N'T/\J0RW1110!8L?^/N+_>K>K!L?^/N+_>K>H`P]
M3_X_'^@_E56K6I_\?C_0?RJK0`4444`%%%%`!1110`4444`%+24HZT`<SXKU
M1PPL[<E1MW2D'KZ"N;"@=!6AXA_Y#MR!TPO_`*"*H5NMCQZ\W*;N%!.!D]J*
M#R#3,C(8;68'J#25<N;8G+)][J1ZU4((ZT`)1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4Z.1HI`T;%64Y!'44VC&:!IV9WFB:E_:=BLCX\Q?E?'J/\`
M]=7ZYWP;Q#=#MN7_`-FKHJPEN>Q0ES4TP_$#ZFN0OOC#X"TR\GM-1\<>#[2Z
MMI6BG@GURVC>)U.&5E+Y!!!!!Y%97[0?C^]^&/P=\3>(]%@DGO[*V5+9E7<(
M))'6-9B/1"X<_P"[VZU^2$LTD\KRW#O)+(Q9W=LLS'J2>YS7#B\7[%I)79]W
MPKP@LWHSK5:CC%.RM;5[L_:RQOK;5+*"\TV>&ZM+J-98)X)`\<J,,JRL.""#
MD$<5I6`P9"?3%?)'_!/[XBW^O_#G6/#VMB3[+X4N(_LE[*0$$4^YO)+$]596
M/LKJ.,"OK:TO;-R(K:[MYI#D[4E5B?P%=5*I[2FIVW/E\XP7]G8^IA)R5XO[
MUNOO5BW1115G`%%%%`!1110`4444`%%%%`!1110`RY_U8JK5JY_U8JK0`444
M4`%(3BE'6FMUH`0\G-!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>
M["F2_<;_`'33Z9+]QO\`=--$RV..:DI6I*W6QX\MPHHHH$%%%%`!1110`444
M4`%%%%`!1110`HKOM$&_2+;=S\@K@5ZUUOA[7(#;16MPPAD0;5+'AN>*BHKH
M[L%)*;N;+*5//3L:;4LH^7Z5%61ZY:M.C?A5NJEIT;\*MUF]REL%2VW^N'T/
M\JBS5BWB((=ACT%(98HHHH`L6/\`Q]Q?[U;U8-C_`,?<7^]6]0!AZG_Q^/\`
M0?RJK5K4_P#C\?Z#^55:`"BBB@`HHHH`****`"BE^E<]XC\;Z9X=0K/+Y]UV
MMXF!;_@1Z+347+1$5*D*<>:;LCH.N,<YZ4HZUX7K_CS5M>D(:<VMMGY88&*C
M\3G)_E[5=\.?$G4='V0WV[4+4'[KM^\0?[+=_H<UM]7E8\Y9O0YK.]NYUOB+
M_D/77T7_`-!%4*9-XCL?$.J7$VFS!C\H:)OE=?E'53SCWI]5RM+4PG.,I.47
M=!1112)#&:BFMEE'0`^HJ6B@#-FMVB'(R/45#FM=ER#[U7ELU;++P>X]:`*%
M%/>)HSAQBF4`%%%%`!1110`4444`%%%%`!1110`4444`=3X-_P!3<_[R_P#L
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MX&^-`I`/3`3/S*:\^\#>,K_X?>+--U_1&VW6FS"3;T$J='C/LRD@_6NI\/Z2
M_P`0?AW<V<]S:6=UX0G22RO;Z800FVN7.^W,C?+N$N)$!_O3>E3^#OA?!'K8
MO/$&HZ!JVG:7;S7]SI^F:M%//=K!&TGE*JG.&V88CHNX]J]_#TZ.&H>QZ1T]
M3\8SG&9EG6:O,FVY5&I)]O+Y-?J??-C\5?"EWI]E=7>OZ/IK7UK%<K;7M_%#
M-&LB*ZAT9@P.&'&*Z+3=5LM9L4O=(N[6^LY03'<6TRR1O@X.&4D'!!'7M7Y3
M:_KMYXFUN]U75I/,O+^=I9F`P,D]%'8`8`'8`#M7U%^Q!\0KUGUOP;=I-/9+
M;OJ%I*!D6Q!"R*3V#%E(]P?6O+Q64>RHNI&6W3^NQ]OD?';QV/CA*M.REHI*
M^_2ZZ7_`^L](UO3O$%I]JT#4++4[7<4\^SG69-PZC<I(R/2IK/4+748'FL+F
MWN88G>-Y(9`ZJZ$AU)'&0001V((-?-/[-[?\*XT_P/G,7AWXDZ1#R>4M]9AC
MQ_P'SXAZ\O%[U/IL9U[0/#_@^ZDFBTCQ7\0M?35?)<H;BW@N+R<V[,.0KLBA
ML<E=P[UXQ^CGNNF_$;PIK.KG2M(\3:!>ZF"1]C@U*)Y21U`0-DFMFTU&TOYK
MF*RNK>XELY/*N4BE#F%\`['`/RM@@X/."#7(^,?A)X6\4^#YM&.D:=IZ0PDZ
M?<6=ND+Z?*H_=RQ,N"I4@'@C..>*\K^!_BB\7QEX;U+66;;\4_"L-Q+*W_+7
M5;!1'*P'0>9`5?C^Y0!]`OJ5G'J$5A)=6R7T\;2Q6K2J)712`6"YR5!(&1QD
M@5BR?$KPC%K(TB7Q3X=352_E_8FU.$3;LXV[-V<Y[=:\*\::M<^(?$'C7Q!I
MUS/:QWFLZ9X!TZ^@?8]K`URGV^1#V8O*8PPZ&,>E>W-\*/!A\+_\(X?#.C'1
M?*\LVAM5QC&,[OO;^^_.[/.<T`=/<3Q6D#S7<D<,,2EGDD;:J@=22>U8>C?$
M'PMXBOFLM`\2:#J5ZO6WM-1BFD]_E5B:\(\((?'NI^$O`7B^>75=$\/SZX;I
M+H9&K?V?>);6BR_WU59=Q!R&903G%>^1Z)X;T.]T^2/3]$L+T%H-/9;>**0$
MH24BX!^XK9"]@>PH`JW7Q,\'V5U+;7GBOPU#<0.8Y8I-6@5D<'!5@6X((P0:
MUQKNFMJW]E)J%BVIB'S_`+$+A?.\O^_Y>=VWWQBO$/A=XETFUM=8M+[P;KVJ
M3GQ9K"M?VWA\W,)W:A-_RUQT7.#Z8/I6?\1]&O8/BYXM\9>&(VFUWP+IFC7\
M4"#FZM&^V"[MO^!Q98?[4:4`?0-UJ-J+M;$W-O\`;6B\X6_FKYGE@XW[<YVY
M(&<8S3:\RM=7M/$'QVT74](G6YL-1\`O<VTR])(WO(RI_(BO3:`"BBB@`'6F
MM]XTX=::WWC0`E!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>["F2
M_<;_`'33Z9,0L3LQP%4Y-,F6QQS4E*:2MUL>.]PHHHH$%%%%`!1110`4444`
M%%%%`!1110`9Q1DT44`2W/B^[\.67FH!<P(Z@Q2$_=)&<'M71^'?&>F^)$Q9
MRF.XQEK>7`8?3L1]*\^\6?\`($E_WT_]"%<-&[1.KQLR.IRK*<$'U%:*C&<;
MF,LRJX>KR[KL?4%F<J_L16A'`TG^R/4UP/P6UV]U^UU-=6F-Q]C,2Q,X&0&W
MYR>_0=:]*["N"<>631]/AJ\:U)5([,9'"D62!DGN:?114FX4444`6+'_`(^X
MO]ZMZL&Q_P"/N+_>K>H`P]3_`./Q_H/Y55JUJ?\`Q^/]!_*JM`!1110`4444
M`%5=5U6VT6RDN]0D\N&/J0,DGL`.YJV.M<3\7?\`D6(O^OU/_07JHJ[2,,34
M=.C*:W1R_B7XHWVIEX-'#6%L<C?NS*X^O1?P_.N(8EV+.<L3DD\DTE%=ZBH[
M'R%7$5*KO-W"BBBF8',ZG/)::L\MK(\4B$%61L$<"NK\/_$N2,+!KR-*N?\`
MCXC'('^TO?\`#\JY#6_^0E+]1_Z"*HCK6W+&4=3&%>I2DW%GT#;SI<PI+`P>
M.10R..C`C(J2LSP;;2OX:T[Y=H-NN"W&:VS8R8RNT^V:X)*SL?2TTY13MN5Z
M*4JR$B0%3GO24AO3<****`$90PP<54FLN\9'TJY10!D$%3A@0?>DK4>!9!AN
M:J2V;+DIR/2@"M12D8-)0`4444`%%%%`!113D1I&PBD_TH`;4L<#2'Y>GK5F
M"R`YD.3Z5:`P.*`.@\$6RI#=MU(9>OT-=0.U<[X-_P!3>?[Z?UKHSUK&:]X]
M;#?PD0WMI!J-I/:WL2S6US&T<T3C*R(PP5/L037Q?KW["GB<ZW>_\(SK/AY=
M),[&R%Y<3B98B<JK@1$;@"!D$YQ7VK171AL95P]^3J>;G&08'->3ZU%OEO:S
MMN?G%\9_"-_\)+/2/`]XJLP3^U+^\BSY5].^Z-=A(!*1HI49`.YY#C#"O._#
MVO7OA;7+'5M&E\J]T^9986QD9!Z$=U(R".X)%?H9^T%\"X_C7H5A#:74.FZK
MI=P7M[N2,NIC<`21L!S@X4@]BN.YKR;X??L23^'?&.EZGXLUO3=4TW3YO/DL
MXK=U,[+RBG=QMW;21W`QWKV\/F5'V%ZCUZKN?EN:\&YDLSY<+!NGIRRNO=6F
M]]=#D+[]C'Q-XFN/[8\-76A:/I>JQQWEOIVHSSK-9"1`[0.%B8?(Q9.O(4$\
MU]!?L\?`\_!KPA>6^IS6EWKFJRE[RXMLF,(N1&BEE!*@$MT!RY]J]<Z#`&`*
M2O&KX^O6AR2>A^CY;PIEN`Q'UFE%\_=O37=I=#RFQ^#-Q<?`+2_`NLW-O#K.
ME6$0M+^U9BMK?0MOAF1BH;"R`=AD;AWJEH_P6UR7X=65AK.JV&F^,--\0W6O
M6>H::'GMX;F6>63;M<(SQLLS(R\<'J<<^QT5QGTAYGJVE_$_Q7I,^BZE_P`(
MCX<AO(C!>ZMIM_<74XC(PYMX7AC5'(S@L[;<YPV!3_'/PLN9O!WA:R^&C6%A
MJ_@:[M9]#^VLRQ%(U\IX9&56;:\3,#@')`KTFB@#S'1O@G!!\$;;P+JU](+S
MR1+<:G;/N=;_`,WSS<HQ`)(G^8$X)``/>I5?XLC3_L+0>`A>*OE_VT+RY8$=
M/-^R>2/GQSL\X+N[XKTFB@#RNZ^"<VD^'_"__""ZN;7Q-X1>XEM=1U!&F34&
MN#NNDN0#G;*YWG:<JP!7CBGW'ASQYXI\4^$+WQ;8^%-/M?#.J/>S2Z?JL]P]
MPS6TT&U(WMT"C,V>7.,=Z]1HH`\M\):!X^\$VFIV%AIO@N^L[C6;^^AFFUNY
MA?9<7,DP#(+1AD!\'YCTZ]ZZC2/"MY8?$CQ/X@N'MC9ZU8:=;P(K$NKVYN-^
MX%0,?OEQ@GOP*ZJB@#Q_X:_!G5_`'Q*O]0-WIDOA*WL+BST*UC9_M-M%/<+<
M>4X*A=B/YBJ0Q.-N:];D@S_J_P`JEHH`I$%3AA@T5=*AAAA5>2W9>5Y7U-`$
M0ZTUOO&GXP:8WWC0`E!Z44'I0!AZC_Q^2?A_(56J76+B.VN9&F8*!C^0KG+W
M77ERMH#&O]]NI_PK=1;2/.J58P;N:MYJ$-DO[QLOV0=36#?ZK+>`J/W<1_A7
MO]35-B6R222>22<YIM:*"1P5,0Y:=`HHHJC!NX4444""BBB@`HHHH`****`"
MBBB@`HHHH`****`,;Q;_`,@27_?3_P!"%<*.E=UXM_Y`DO\`OI_Z$*X4=*ZJ
M7PGD8W^+\O\`,]D_9]Y@UW_>M_\`VI7K/:O)?V??]1KO^];_`/M2O6NU>=7_
M`(C/KLJ_W2'S_,****Q/1"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;U`&'J?\`
MQ^/]!_*JM6M3_P"/Q_H/Y55H`****`"BBB@!1UKB?B[_`,BQ%_U^I_Z"]=L.
MM<3\73_Q3,7_`%^I_P"@O5T_B1RX[_=I^AX_1117H'Q@44^*&2XD"0J78]A6
M_I_AI0`^H$,?^>:GC\:3:1M2H3J/1'G]SI-SJVJS"SC+*&`9SPJ\#J:Z32?"
M-M8;9+K_`$F=>02/E7Z"NCNXTBF98E5%'0+P!Q_]:HAT-)U&]C>GA80=WJSM
M=*&-+M<8`"<`=JM56TO_`)!=M_N59KD;N?14_@0UXDE3;(`:IRV#1_ZK#`]N
MXJ]0#BBX3IJ1DY]>"*,UI36T=P/G^5O[PJA-:O">F5]157.65)IC**0$'H:6
M@R"BBB@"*6V249.0?451E@:(\\CU`K3I"@/6@#(HJ_+9J^=GRD56-K("1M)^
M@H`AI5&XX'6IX[-V^\"H_6KD4"Q#Y<Y]:`*L5D>LGY5;2%4&$&!3Z*`"BBB@
M#IO!O^IO/]]/ZUT9ZUSG@W_57G^^G]:Z,]:RGJSU\,OW*$HI<48J#8,=?;FD
M]?;K[50U_2;77-%N['4K:*\@FC),,@R&8<KQZ@@'->=_\(?J>G_!CP]IGAVV
M_L_6Q/HD]X#$6*2I<VQN))%5U+X57+#<,A3SSP`>J`%L8YR,C%)7DVI>'_%+
M^!?BO:Z@_P!NU;5&N#ILEG`\"SYTRVC3RD,CL/WBLOWN64GC-=OX!L$TWPW#
M;QV\-LR2.76'3)-/0L3G*PNS,.W))R030!T8&3@=?2C!':N$D\*WUS\89];D
MCLO[-M=*LXX'N+1I)#+NN]_DR"0",@-'NRC9!'3BLF?3M;/B;^SDL=3VCQ?'
MJHO,?Z.UDL"Y/F9P/G!3R_O9.=NWYJ`6IZA2XYQW%</<>";1_BM::R-,B:)=
M,FDDN]O'VL2Q>6W^_LWX/ID9[5D7EIK`\1W^EQ:9J;+>^*K+48+P+_HZV4<-
MOYF9"<#YX9%\O[Q+`X(;-`'IXY&1TH"E@"O.>F*\D\0>$-=G^*T&MVUNO]EQ
M7]BLDT43?:A&(Y`Q1]^/*WF-9$*G*L2#\HK7@T2X7XR7VHWMK'):O!"MG,^E
MRRL#Y3!RMP'V1C+-E2A))Z\T6`]$`)Z4F<G`ZUS?Q%LM1U#P=?0:"+F2Y=X&
MD@M9O)FN+=9T:>*-]R[7>$2H#N'+#D=1B>`M)>UU_6Y]$TR^T7PU/96RV]E=
M*T&^[4R^=*D)YC!5HE)P-[*6`XW,`=^.1D<BBN'^"_A2]\(_#W2;77([*+4I
M+.W>Z6WM&@82^2@82YD??(&#9?(!/85W-`"444N*%J`E%%%`#3&K9XP3WJI(
MC*YSS]*NU#)]YOK0!5Z].M.$18?,.#4H4#H!3AUH`\V\8$_V_<J22%V8!/3Y
M!6+6SXP!'B&[S_L?^@+6-79'8^=Q'\67J%%%%,Q"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`QO%O\`R!)?]]/_`$(5PHZ5W7BW_D"2_P"^G_H0
MKA1TKJI?">1C?XOR_P`SV/\`9]_U&N_[UO\`^U*]:[5Y-^S^I6VUMB"%9X0#
MC@D!^/UKUGM7G5_XC/KLJ_W2'S_,****Q/1"BBB@"Q8_\?<7^]6]6#8_\?<7
M^]6]0!AZG_Q^/]!_*JM6M3_X_'^@_E56@`HHHH`****`"N:^(6AW.O\`A\PZ
M<HDGAF658^A<`$$#WYKI:1G"''4]Q33L[F=6FJD'![,^;IH)+>=H9XWCF4X:
M-E(8'TQ6MI_AV6?Y[L^2G]TCYC_A7L^J:1:ZLX>ZA1I$4A)0,,H]`:Y?4_#5
MQ8C?#F>(=UZK]1_A74JZ:MU/"EE7LGS/5&!;6<-I'LMD6,'J1U/XU/1VS2JI
M=@J`DGH!2UO=EI):(R;[FX;\*9;V\ES)Y<",[GL.WU]*WE\-22W)>_)B3@[`
M/F/^%;-O:Q6D02W144>G]30YHJ&&<G>6@EG";:SAB<@M&N&QZU+1161Z$596
M"BBB@84`X_&BB@"O+9I)EH\(W\ZIRQ/`V)!QZXXK4H8!EPP!![$9JDS&I14M
M49`8'I2U:FL!DFW/_`355_D;:X(;T(IG+*$HO4****"`HHHH&%%%%`!1110`
M4444`9^O?%C2OA=I\?\`:-MJ&I:EJ]PL&FZ9IT/FW%VXZA5XSC*_F.#72_#7
MXBR^/X-0^W^&O$'AF[TV14EAU:W\OS"P)!1OX@`.>.,CK7G?C7P1XEU37/#7
MB_X=Q6=_K'@^ZG)TV[E$2W<5Q&$<*YX5@JD<D?>SG(P?1OAWK?C776U"?X@^
M'=.\-VVZ-=/M8=1%U-C!WF5E^3&=N,$'J".`3K4A#V*DK7]=5KV,,'7Q+QKI
MU&U!/1*%XM<M[N=M'S75KKIIK<R]7^-VC:-\6=.\!SV]T]]?QJ3=KM$,$CJ[
M)$V3G<P08_WAZ&M#XN_%*R^$/A,:]JUG=7UL;N.W,=L5#98$@_,<8^6O!]>^
M!7Q'U^3Q'XRANK>QURX\10ZE8:%)%"\D@MF*VQ^T^9A=L4C_`"]#CZ5ZE^T/
MX/U[XC_#;3;/P_IHEU`ZI:W5Q:2SQCRD56W@LS;3@D#@G-5*CAU.FD].IST\
M?FD\-BG*DU)7=/W>CO96UNU;5/77;8Z/1?BWI?B+QS8>'=&AGN%U/P\NN6]^
MK+Y1A:0QA",[@V1GVJA\1?C79^!==M=`TS1-:\4^(KN`W']FZ3!YCP0Y(\R0
M_P`()'OVSC(SQ/PK^"&L_#?X[:C?6R^=X-31YH-(E,RDVJRSK-]FVYW#:YEP
M<8((.<G`T_&WA#QCX1^+LGCWX<Z3:>)8=6TM=/U'3)+Q;26,JPVR([_+MPB\
M=<YXYR!TL.JMD[JW>UWYOH7]<S26!<YP<9\]G:-VH]TOM:[/71WUL>D>#/&/
M_"8>%H]9?2-6T5B9%DL=3M_*G1D)#9&>F0<'O7$_##X]O\4]0LAIW@[Q-9:7
M>K*4U:YB4VH*9!&\'J64K]:[+P;=>)M7\*-+X]TW3]*U><R[;.RN?.6*,D[%
M9NF\`X."1D9XS@>'_LV?#+Q+\--3L(?$7@.:TN989X;W7?\`A(TE18RQD4"U
M5B,DJBY'/?N:B%.DX5&]UMK_`,'7\2Z^*QL<3A(POR23YGRZ[QM=<KY;ZZ/E
M]3T3XE?'BW^'/BR+04\-:YK]VVE_VE)_9JH_EP!W5B02#@;"2>G-=UX-\66'
MCKPOIVO:$TC6&IPB2+S``Z\D%6`)`(((/)Y'>O%OC/\`!77?B5\4C>Z;/=Z;
MIO\`PB,EG'?V]ZL.;OS9&6*1<[FC8.`P`P0>M>H?![3;_1?AKH.FZ]I$6AW^
MG6JVTUI%,LJY3C>&4D'=][KG).<]:*U.BJ,91^+J:9?B,QEF=:%>+]EKRZ66
MC75+\]^FS+?Q!\977@C1(]0T_P`/ZSXD=[@1/:Z7$'DC4JS&1A_=&T#_`(%7
M,_"7XV-\67#V/A77M+TQ[9YH=4NT4V\S)($,:L.K9+<?[)KT>[C:6TG2,?-)
M&RCG')'_`-:O/?V=O!VK>!/A!HFB>*;;['J-HUQYL/F+)LW3R.OS*2#PP/7O
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M6^IWT:BWGPRJ$5AU)R3_`,!-9?Q`_:+M/`7B_4]#?PQX@U?^Q;.*\O[JP1'2
M"!@#O8$Y`&>2<"N>_9G\!Z]\.I?L6N^")=$DGLMM]K!\1)=I<.C955MU)\O.
MYNAQQ61\8/@)XG^('Q%\9ZII;W=C;76@PIIDL-^D4=]/'LW6\J[@Q5@&`)PN
M<$GC%:JCAO;R3:Y>FOGY,X:N,SC^R:52G%NLWJN76W*W:SC'2Z2O;RNV?0^@
MZY:>)-!L=8TMRUEJ5K'<P/(NT^6ZA@2.QP:XGX1?''1?C#-K4>@VUS:G1YE7
M-PR_Z1&Q8+(F#T^1LCMWJ'6+/Q*_P%ET[P]X>&G^)'T5;"+28;B)%M&($1V/
MOV[53<ZG=G`&>>*X7X:?!CQC\*/B-X>O?MUIK^CSZ*VE:B]O:1V9L4CP\1*^
M83,2Y(W@;L9S6,:5+DFVU?6VO;_,]&KC<?'$X90IMP:7.U'K+1;ZJSU:MHM[
M'9_$KX[P?#SQ8F@1>&]>U^\.E'4Y#ID:OY<`=U8D9S@;,D^];<GQ5L;GX4GQ
M[X?L;W5M-%H;K[-"56;8I(D&"<93#9&?X3BN#^)OP6U/XB_&ZVU!KO6-)\.#
MPP;*?4-)OXX)6F\Z0F`@[CL9'Y^7!XKUSPKX3T[P;X8L=`T.'9IUA`8HD<[B
MP))8MZEB23ZDFE46'C3A;?J:8669UL57532GJHMI7OI9K2[6^][]#D?"GQNT
MKQQXML-$\*V=Y?+<Z-'JEU>J5$5BL@^6*3G/F$XX]_8UZ,>O'2O(_P!G?X93
M_#:P\5Q:CI<.FR7_`(AGDL_+E20O9*%$`RI.`,O@'D;CQS7K=8XA4U.U/8Z\
MGGBYX6-3%?&^EK6\N_GKW"H7^^WUJ:H7^^WUK$]0;2TE%`')^-="DN"+ZT4N
M47;*H&3@="*XG\#7L58>L>$[35-SQ@6UP?XX^C?45M3J=&>=B<$Y-S@><XQ1
M6EJN@WFD,?M49:/M*@RI_'M^-9P&:W33V/*E"479JPE%!&**"0HHHH`****`
M"BBB@`HHHH`****`"C&:,5>L=(GOB"B^7'_?8<'Z4-V*C!MV*./4@'ZT$8-=
MC8Z5!8K\J[Y"/F=N_P#A2W>EV]ZI$B`,>CJ,$5G[17.KZG*V^IYKXMXT67/]
M]/\`T(5Q=C87&I7<5K80R7%Q,VU(XUR6->T7'PWEUP?9KBZ%O;,RL9`F7(!Y
M`!XS[UV_ASPEI?A6W\O1[98V8?O)F^:1S[M_3I6T<1&,+'$\IJUZW-+2/];%
M7P%X7_X1+P[!:2$-<N?-N&7H7('`]@!BNAI:2N&3;=V?34Z<:<%".R"BBBD6
M%%%%`%BQ_P"/N+_>K>K!L?\`C[B_WJWJ`,/4_P#C\?Z#^55:M:G_`,?C_0?R
MJK0`444O\J`$H9@HY/X4QI>H`_&HCR<GDT`/9R3P<"F444`%'7KVHHH`R]1\
M.VNH-OP89/[R=_J*FT[1[;3`#"FZ0=9&.6/^%7J*?.TB%2@G>VI@:IQ>R@>H
M_D*J5;U7_C^E^H_D*J5HC"6X4444""BBB@`HHHH`****`"DDC25<2<^_>EHI
MW$TFK,HRV+)EHLNH[>E5\_7BM8$BHYK>.<?,"&]133.>I1[&;FBGRV[0.`W(
M/1J93.>2LPHHHH$%%%%`!11FBBP'3>#<>5>9_OI_6NCKG/!O^IO/]]/ZUT9Z
MUE4W/6PW\)!DX^M`)!X.*2BH-P[8XI<GVI**`%SD\_K1T&,"DHH`7<:"Q/4D
MTE%`!2YI**`#Z@?E2]1_/WI**`%SQU/YT9)__7244`*"1CMCICM1DXZGFDHH
M`7/K2444`+G-)12T`%5W/SM]:KZMKMEHD>Z^F4-_#$OS.WX?XUS4_B275HR\
M"F"%R1MW98@$CDU:@VKF4Z].#LWJ;E]K,%H2F?,D[A3T^M4U\3#/S0MM]G&?
MY5@YH!Q5\B.66(FWH=E::A!>)F%_F[J>"*L5PZ2-&P:,E6'0@]*V+/Q"R@+>
M@D=G7K^(J7#L;0Q">C-YXTD0I(JLK=01D&N8UCP5%-NETQA"YY\MLE3]/3^5
M=+!/'<1AH'$BGN*EJ5)Q-9TX5%JCR.]LI[";RKN-HW'KW^GK4!&*];O+&#4(
M3%=QI(A[,.GT/45QVL^"I+?=)I3&:,G_`%3??'T]:WA4ON>57P4H*\=4<K13
MI(FB<I*I1UZJPP132,&M#A:L%%%%`@HHHH`***?%$\T@2)2S-T`%#=AI7&XJ
M:ULIKQ]L"%O4]A6Q8>'#Q)?G'I&I_F:W(XTA39$JH@_A48%0YHZZ>$;^(R[#
M0(8,/<_OG[`_='X=ZUJ='$TIP@)J_!IZJ`9AN;L,\"L92OK<]&E225DBI!:O
M<'Y>%'<U?@LTA&2-S>IJP!M&!Q14.3.B,$@QZ_SJ6.X9.#\R^E144BR^D@D^
MZ1GTI:H`D=#CZ5-'<G@.,CUH`LT4`AAE2#]**`"BBB@"Q8_\?<7^]6]6#8_\
M?<7^]6]0!AZG_P`?C_0?RJK5K4_^/Q_H/Y55H`*;*2%&/XJ=3)ONK^-`$5%%
M%`!1110`4444`%%%%`&#JH(O7)_BP1^0JG70WUDMW%\IV2*/E/;\:PY[=[=L
M2*1Z'L?H:TCL<THM,BHHHIDA1110`4444`%%%%`!1110`4444`-F031,OJ.*
MREX'-;"]:QT^Z/I5(Y*\4FA:***I;F`R:9($+RL%11DL2`!7*:SXZCBW1:0J
MROT,K_='T'>H?B"[JUH@=MC%SM[9&T5QW2NFG25KGGXC$SC)QB='IOC>\MY?
M^)A_I,1.3D`,OTQ7::;K-KJL>^SD#$#YE)PR_A7E%:_A[2[BXU"UD0F&/S5_
M>=\9Z"B=-:F>'Q%1.VY[OX.B86MQ(1A9'&W\.O\`.N@-16UO':P)%`H5$&`!
M4E>?)W9]=3AR040HHHJ2PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*4
M]*1B%&7(4`9))KD];\?VUGNBTD+<S=/,S\B_X_YYJE%O8RJUHTHWDSI[N\@L
M(&FO94AC7J6.*XC6_B!+*Q@T)"`>/.<98_1>U<KJ.I7.JW!FOI6D<]!T`]@.
M@K7\'(IFN6*C>H7:WIG.:W4%"-V>;+&3K5%"&B_$;9^&[B_D\_5WD0.<X9LN
MWU]*Z--'@%LB6X,6T8'.?SJ7-68ON`5+DV=5*A3@N]_O,.XM)+8_O%^7LPZ&
MH:Z1U#(P.""*YS&,^QH1G5I\K$H!Q113,R6WNY;5]T#E3W]#]:WK#Q!'*`EW
MB)^@/8USE`XJ7%,N%64-CNE(=05((/0@TM<?9:E-9']TP*=T8<&N@T_5X+T!
M0?+D/\#\?D>]9N+1VPK1EOH-U70K35T/VF/$F.)$&&'^-<3J_A2[TS=)&#<6
MX_C1>0/<5Z1T-)BG&;3,ZV%IU-]SQ['I2$8KT36/"-KJ6Z2#;;3DYW*ORL?<
M#^8KBM3T2ZTB0+=Q_(?NR+]TUO&I%GDUL+4IO78H44459S`.M=%X9A3R9I<#
M>6VY]L9_K7.CK78^&-,F6T)G1HED?<N\8)&!SBHJ-)'7A(-U$70"S849/H*M
MPV!)!F./]FKL5ND(&Q0#W..34E<[EV/8A3MN-1%1<*`!3J**DU"BBB@`HHHH
M`****`)K8D2X[$5:JI;_`.M'T-6Z`"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;
MU`%&[@C,N60$D<G)J'[/%_SS'YG_`!HHI`'V>+_GF/S/^-(;6%NL8X_VC_C1
M10`GV.#_`)YC_OH_XT?8X/\`GF/^^C_C110`?8X/^>8_[Z/^-'V.#_GF/^^C
M_C110`?8X/\`GF/^^C_C1]C@_P">8_[Z/^-%%`!]C@_YYC_OH_XT?8X/^>8_
M[Z/^-%%`!]C@_P">0_[Z/^-,DTZVE4K)"K`]BQ_QHHHNP:ON5_\`A'M._P"?
M4?\`?Q_\:/\`A'M._P"?4?\`?Q_\:**+L7*NP?\`"/:=_P`^H_[^/_C1_P`(
M]IW_`#ZC_OX_^-%%%V+E78/^$>T[_GU'_?Q_\:/^$>T[_GU'_?Q_\:**+L.5
M=@_X1[3O^?4?]_'_`,:='X=TUG`-J,'_`*:/_C11338<J[%G_A%=+_Y]?_(K
M_P"-'_"*Z7_SZ_\`D5_\:**=V'*NP?\`"*Z7_P`^O_D5_P#&C_A%=+_Y]?\`
MR*_^-%%%V'*NP?\`"*Z7_P`^O_D5_P#&H1X)T4=+/_R-)_\`%444KL3IP>Z#
M_A"M&_Y\_P#R,_\`\51_PA6C?\^?_D:3_P"*HHH4GW%[&G_*ON*.H_##PSJQ
M0ZAIOFF/.W_295QGKT8>E4_^%,>#O^@/_P"3D_\`\7115>TFMF2\-1;NX+[D
M/C^#OA")U=-'&5Z9NYB/R+U>C^'/AV)U:/3\,A!4_:)>,?\``J**/:3?4%AJ
M*V@ON1N?V=;_`///_P`>/^-']G6__//_`,>/^-%%2;!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>
M/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`%/4?#&G:M$([^!Y(QSL$[J#]0&&?QK
M._X5MX<_Z!W_`),R_P#Q5%%--K8SE2IRWB@_X5MX<_Z!W_DS+_\`%58L_`^B
M:>6-I9>67QN_?R'./JU%%/FEW!4::=U%?<6O^$9TW_GV_P#(K_XTJ^'-.3.V
MWQG_`*:-_C112NR^5=AW_"/Z>1_Q[_\`D1O\:K?\(;H__/H?^_TG_P`5111=
MB<4]T)_PAFC_`//H?^_S_P#Q5'_"&:/_`,^A_P"_S_\`Q5%%',^Y/)'L'_"&
M:/\`\^A_[_/_`/%4?\(9H_\`SZ'_`+_/_P#%444<S[AR1[!_PANC_P#/H?\`
MO\__`,52CP=I`.1:$$?]-Y/_`(JBBB[*4(]B['HUG$@1(CM7IF1C_,T[^RK7
M_GE_X^W^-%%(H/[*M?\`GE_X^?\`&F2Z+931LDL"NC#!!)(/ZT44`9)^'?AX
MG/\`9_Y7$O\`\51_PKKP]_T#S_X$R_\`Q5%%5S2[F7L*7\J^XEM?`>A6<PE@
ML%$B]"TKMC\V-:7]C6?_`#Q_\?;_`!HHI-M[E1IPCLK!_8UG_P`\?_'V_P`:
M/[&L_P#GC_X^W^-%%(L/[&L_^>/_`(^W^-']C6?_`#Q_\?;_`!HHH`/[&L_^
M>/\`X^W^-']C6?\`SQ_\?;_&BB@`_L:S_P">/_C[?XT?V-9_\\?_`!]O\:**
M`#^QK/\`YX_^/M_C1_8UG_SQ_P#'V_QHHH`5=)M$.5BP?]]O\:?_`&=;_P#/
M/_QX_P"-%%`!_9UO_P`\_P#QX_XT?V=;_P#//_QX_P"-%%`"QV$$3AT3##H=
(QJQ110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g852948002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g852948002.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"``S`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]0;K4I8+AT18R%Z9!_P`:A_M>;^[%^1_QJ+4/^/R7ZC^55J`+W]KS
M?W8OR/\`C1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO
M-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_
M=B_(_P"-']KS?W8OR/\`C5&EH`N_VO-_=B_(_P"-']KS?W8OR/\`C7+ZEXGB
ML9VAAB:=T.'.=H!]/>LN7Q9>/D1I!&#T^4DC]:KD9A+$TXZ7.\_M>;^[%^1_
MQH;6944LPA`'<@_XUYO-KE_.H#W,@Q_<PG\L52E=IF+2LSL1]YCD_G5>S,98
MU=$=Y/X]CMQEY[$C.,)EB/P!JE+\4(X_N(LOH4C.#^;"O.71D/S@BFTU!&,L
M9-[([N;XK71!%O96X/8NQ/Z`_P!:K_\`"U-5_P"?;3_^_;__`!5<913Y49O$
M57U.S_X6IJO_`#[Z?_W[?_XJC_A:FJ_\^^G_`/?M_P#XJN,HI\J%[>IW.S_X
M6IJO_/OI_P#W[?\`^*H_X6IJO_/OI_\`W[?_`.*KC**.5![>IW.S_P"%J:K_
M`,^^G_\`?M__`(JC_A:FJ_\`/OI__?M__BJXRBCE0>WJ=SL_^%J:K_S[Z?\`
M]^W_`/BJ='\5=3##S;6Q9>X57!_/<:XJBCE0>WJ=ST"'XK2-_P`?%FB?[F6_
MF15V+XE02XR\,9/9XG'ZYKS*BDX(T6+J+?4]:B\9F=ML$EC(?16R?YU/_P`)
M+<_W+?\`[Y/^->/5-#>7%NN()Y8QZ*Y`J?9FL<;W1ZW_`,)+=?\`/.#_`+Y/
M^-'_``DMU_SS@_[Y/^->9P^)M0A(S,L@`Z/&#_+FKD/C*8$_:;:-_0QL5_QI
M<C-HXNFST#_A);K_`)YP?]\G_&C_`(26Z_YYP?\`?)_QKGM-U.'5(2]ON&T@
M,K#!!JW4/0Z(R4E=&M_PDMU_SS@_[Y/^-'_"2W7_`#S@_P"^3_C6310,UO\`
MA);K_GG!_P!\G_&I[77KB?=O2$;1V!_QK"J[8HR!RPQD<4`:W]KS?W8OR/\`
MC1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_X
MT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_P"-
M']KS?W8OR/\`C5&B@"]_:\W]V+\C_C1_:\W]V+\C_C5&B@"ZVM2H,LL>/8'_
M`!J,^().R1G\#_C5*X_U?XU6H`TSX@N.R0C\#_C1_P`)!<?W(?\`OD_XUF44
M`:?_``D%Q_<A_P"^3_C1_P`)!<?W(?\`OD_XUF4$XH`T_P#A(+C^Y#_WR?\`
M&C_A(+C^Y#_WR?\`&LK=1N-`%'5_B'J-AJ,D$,%DR(%P61B>0#_>JH/B;JS'
M"6UBQ]!$Y_\`9J@U2)'OY&=$+<<E1Z5"`!TK6R['`_:<S]XN3>/O$TO-G!I4
M8QTFM9#_`.U151_'?C=&)$/AAHQZ13[ORWX_6DI#T/T_K3NNQ,HR?VG]Y'!\
M6-?4YN8]'<>B6TBX_$RFIO\`A;6L?\^VF_\`?M__`(NN)_A%%:\D>QP/$UD[
M<S.V_P"%M:Q_S[:;_P!^W_\`BZ/^%M:Q_P`^VF_]^W_^+KB:*.2/87UJM_,=
MM_PMK6/^?;3?^_;_`/Q='_"VM8_Y]M-_[]O_`/%UQ-%')'L'UJM_,=M_PMK6
M/^?;3?\`OV__`,71_P`+:UC_`)]M-_[]O_\`%UQ-%')'L'UJM_,=M_PMK6/^
M?;3?^_;_`/Q=0S_%C7F(^S1:0@QSOMI&_E(*X^BCDCV#ZS6_F.BF^+?C!#^X
MMO#DB^\,RG_T9_6J,_QL\;6XR^CZ,1G'R0R/_*6LNBJ2CV,G5KO:HT32_M#^
M*H'VSZ;HT;?W7MYE/ZR5'_PT?XE_Y\=#_P"_,O\`\<IO48/0]:IS:/8S@B6T
M@Y.253:?S%4E3ZQ,7/&=*K+W_#1_B7_GQT/_`+\R_P#QRN@T3XJ>/=>MH[FR
MTG0!:RYVS2*X!P<'CS<]0>W:N#F\(Z?*1L$T/^X^?YYKT?P78)8>&[6UADWK
M&7))ZC+DX/YTJGLTKQ1O@EBZE6U6H[>3-FS\5^,''^GOX:A.>D-K/+_.1:U[
M?Q;J*Q*+H64DO=HX60'\"Y_G62R%>OYTVN9V9[\(<O5OU.A@\4W<N[=';C`[
M*?\`&K(\17&>8X2/H?\`&N>L_P"/Z5<K-[FJ-<>(I?XHX_P!_P`:D37G<X"I
MGW4_XUB5)!_K5^M(9M?VO-_=B_(_XT?VO-_=B_(_XU1HH`T8=5EDF1&6/#,`
M<`^OUK4KG[7_`(^8?^NB_P`ZZ`=*`,/4/^/R7ZC^55JLZA_Q^2_4?RJM0`44
M44`%%%%`!3)YXK:,R7,L<4:]7=@H'U)I]<%\8<?V/8_]?)_]!-5&/,TC'$U?
M94G4['0WGCC0;''G:I;-G_GB3+_Z`#6+=_%K2(=PM8KRX8?=(0*I_$G(_*O(
M*/Z5U*A%'S\\YKOX4D>C7'QCE8$6FEQH>QDG+?H`/YU8MOC)&7`O-+=%[M%/
MN/Y$#^=>:102S_ZB.23_`'%)JY'H5[*JD0E0W]X@8_#K3=*'8RCF&->S_!?Y
M'07OQ*T2XU.Y,KW-MF1C^]A)_P#0<U;M?$VDWH3[-J%HQ?A5,H5C_P`!/->>
M77@BYGOIGGGAB5G)&T%C^7%3VW@6V3_CXN9I,'^`!!_6K<*=MR(XC%-MN*_(
M]/!!Z'-%3:3IMO;:3911HQ6*!%7+'H%%6_LL7]S]37.VCUHT)-)F:5!Z@4QK
M>-NJ+^`Q6D;*,]"P_&HS8'^%Q^(I70.C-&:UC&>A(J(Z>>S@_A6H;.4=`&^A
M_P`:C,3KG<C#'M3,W%K=&8;*4=@?H:B:&1>J-Q[5J@@G@YHQ0(Q\T5KE%;[R
M@_45&UK$W\(!]J`,RBK[6"'[K$5$U@X/RL#^E`%6BIC:2C^'/T--\B3_`)YO
M_P!\F@".BI!;RGI&WXC%2+92'J`OU-`%>BKBZ?\`WG_(5(+&,=<GZT`9]*%)
MZ`GZ"M18(T'RHOY4\#'2@#6\&6TK6]R0A`\Q>3QV/^-=*MDY^\5'ZUF^#O\`
MCVN_^NB_RKH#UK&:LSU\-_"15%BO\3D_08J06L0_A)^IJ6BI-A%14^XJK]!2
MT44`%%%%`!1110`4444`%%%%`!1110`4444`-E4NF%ZU6:-EZJ?PYJW2T`4<
M45=(!ZC--,2-U44`5*1_O&K1MU[9%0/"0YYH`BHI_E-[4OD\<F@#G]2_X_9/
MP_E5:J'BG4[BUU>>&`JBJ%(;;DGY16%)J5S)]^:3GKAL#\A70H71Y57$QC-H
MZJ21(EW2,J+ZL<"JL^JVL(.Z96..`GS9_*N6)W')Y-%5[,PEBV]D'844459R
M-W84444""BBB@`HHHH`****`"BBB@`HHHH`*56*'*D@CH0:2B@+B:MXBU+3M
M+N)K2\F61%&TN=^.1V;(KG[/XL:Y;*!/]CN^>6EAP?\`QT@?I5_Q'_R!+K_=
M'_H0KSZMZ<(R6J.'%8JO2J+DFT>]_#GQB?&<][&UJ+0VRIR)=^[<3VP,=*[X
M6J+][+?C7CWP"4_;-7;!VA8<G'NU>S&N"O%1J-(^FRRM.KAHSF[O7\Q@AC'1
M!^/-.`QTHHK(]`****`);7_CYA_ZZ+_.N@'2N?M?^/F'_KHO\ZZ`=*`,/4/^
M/R7ZC^55JN7T$KW<A2.1@2,$*?2H/LLW_/&7_O@T`145+]EF_P">4O\`WP:;
M);3\;89>G.$-`##QUI"ZCO2?8[C_`)X3?]\&C['/_P`\)O\`O@T`'FCWJEJ6
MGVFKPB+4K:*XC4Y`D&=I]0>H/TJ[]CG_`.>$W_?!H^QS_P#/";_O@T)V%)*2
ML]CDIOAMH,AREK)%_N3N?YDU%_PKNSB(^RNB;?NEH0S#\<UV7V.?_GA-_P!\
M&C['/_SPF_[X-7[27<Y_JE#^1'$2>$+Q/]6T#@>C$?TJ2'P=<N?W\T,8_P!G
M+'^E=G]CG_YX3?\`?!H%G/\`\\)O^^#1[20+"4TSSNX\*0QW,HGFED(;'R@+
M_C4D>@V,>,0[B.[,3FNLOO#UU+*TD,<AW')4QD52?0=03K:3D>R$U?.V9?5X
M1?PF>`%4!0%4#``&`*6K?]CW_P#SY7?_`'Y;_"C^Q[__`)\KO_ORW^%*Z+L5
M**M_V/?_`//E=_\`?EO\*/['O_\`GRN_^_+?X470[,J45;_L>_\`^?*[_P"_
M+?X4?V/?_P#/E=_]^6_PHNA6*;*'^^`WU&:C:UB/\`!]N*T/['O_`/GRN_\`
MORW^%']CW_\`SY7?_?EO\*+B<$]T9;6*'[K,OUYJ-K%A]UE/UXK8_L>__P"?
M*[_[\M_A1_8]_P#\^5W_`-^6_P`*?,0Z$7T,1K65?X<_0U$59?O*R_48KH/[
M(O\`_GRN_P#ORW^%']D7_P#SY7?_`'Y;_"CF,WAET.>HZ=*W9-!NY`=UA=9P
M<$0,#_*L\:'J6/\`D'WW_@.W^%.Z,9TI1=BE15[^P]2_Z!]]_P"`[?X4?V'J
M7_0/OO\`P';_``IJQ'++L4:*K:Y%KNFR(ECX?U.\WJ262VD(4^^%KGKB3QK,
M"(M`U.#T*:9+D?F#6BIM]3&=51=K/[CJJ*Y&"/QPK_-H^K29Z!],<#]%%;VE
MVWBJXFCCO_#US$'<*9/*D4*">O1J3A;J*%7F^R_N.Y\'?\>UW_UT7^5=`>M5
M-&T"72H'0K+(TK!F/ED`<=*O_99O^>4O_?!KFF[L]ZC%QII,BHJ7[+-_SQE_
M[X-'V6;_`)XR_P#?!J34BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BI?LLW_`#QE
M_P"^#1]EF_YXR_\`?!H`BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BBX#VR;Y8;D
MC_IG;O(?R4$UF7.MO"<0Z5K=QQG,=@X'_CP%-)LB52,=V:=%<S-XEUGYA;^&
MM1]B\4A_0+_6J]K=^*=49Q);3Z<$P05TYCN_[ZS5>S=KLQ^M0YK)-_+_`#.N
MJM/,D))F=4'JQQ6!)H6J3DM=2:U+N'S*"R(?P4"I+?PNT<>V.QNT&23E7//X
MT<J[E*I-_9-"36+.(X:=3_N@M_*HQKUD?^6C#_@!_P`*IOX6N#DQPW0]C$36
M<=#U')_T"]X/_/!O\*?+%D2JU(O5&U=-I6K)MNS;R@="_P`I'T/!_*J,W@K2
M[CYH#+"O_3.7(/YYJG_8FI?\^%[_`-^&_P`*5=&U-&#)8WRD=Q`P_I5;;,RE
M.,OBA<BF^'_RDVUYD]@\7]<_TK-N/!&I0#*+#/[1R8_GBNACAUR(Y2WU$_[T
M+-_,59BFUM,!]/N9/=K9A_*FI21#HT)?9:.$GT/4+<D2V=QP.2L98#\1Q5(J
M0<8->IQWE_N_>Z3?J.^V)C_2I6C^VIMN]-NRHZ++9LP_D::J/JC-X&#^&1Y-
M17J<O@ZRNQN;370GILC>/'X#%9T_PUA=2;?[;$W;*;A^6,_K356)G++ZJVU/
M/:*[&?X9WRX^S2>9SSYD+)C\LUG7'@/7(2=EA)*J_P`2$<_@>?TJE.+ZF$L-
M6CO$Y^BM+_A&=7'_`#"]1_\``5_\*/\`A&M7_P"@7J/_`("O_A3NC/V<^QFT
M5IIX7UB1PJZ7J&2>]LZC\R,5OZ-X(OD$C:CISALC9O7<,?09I.22+IX><Y6L
M<<%)Z#)]*L1Z9=2D!+>7GH2N!^9KT:#PQ-$N%A>,'JJ0$5870)!U@N6^J&H=
M5';'+WU9YY%X<NY!E_+C_P!YO\,U;B\*EB-\_/=53_Z]=ZNCNO2TE_&,FI!8
M7"C"VTP'H(S4.JS>.!IK<XZ#PG`#S%-)Q_&VW_"ISX-MY!C9Y6>XD)/ZYKJ_
ML-S_`,^\_P#W[-'V&Y_Y]Y_^_9J?:2-OJM+L<5=_#FTOH7@N;JY$$@PPCVAN
MN>"01V]*73_A)X5M$Q<6MU=MG.Z>X;_V3:/TKM/L-S_S[S_]^S1]AN?^?>?_
M`+]FFJLUU(^HX:]W!-^>HFG6=EI=LMOID-O:PKR$B0(,^N/7CK5H$-]TY^E5
MOL-S_P`^\_\`W[-'V*Y'2WG_`._9K,ZDDE9%FBF0VUT'&Z*?!ZY0U8^RS?\`
M/&7_`+X-`R*BI?LLW_/&7_O@T?99O^>,O_?!H`+7_CYA_P"NB_SKH!TK#MK>
M5;B(M%(`'&24/K6X*`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
0B@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
